Mutations in BRCA2 and taxane resistance in prostate cancer

Mutations in BRCA2 and taxane resistance in prostate cancer

Abstract Mutations in BRCA1 or BRCA2 define a subset of prostate cancer patients. Herein, we address the question whether BRCA1/2 mutations have a predictive impact on chemotherapy with docetaxel, a widely used drug in patients with metastatic castration resistant prostate cancer (mCRPC). Fifty-thre...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Cathleen Nientiedt, Martina Heller, Volker Endris, Anna-Lena Volckmar, Stefanie Zschäbitz, María A. Tapia-Laliena, Anette Duensing, Dirk Jäger, Peter Schirmacher, Holger Sültmann, Albrecht Stenzinger, Markus Hohenfellner, Carsten Grüllich, Stefan Duensing
Format: article
Langue:EN
Publié: Nature Portfolio 2017
Sujets:
Medicine
R
Science
Q
Accès en ligne:https://doaj.org/article/b15be919d5ff42faabf1b34d60384950
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Documents similaires